Literature DB >> 22475288

Treating venous thromboembolism in patients with cancer.

Caroline Piatek1, Casey L O'Connell, Howard A Liebman.   

Abstract

Venous thromboembolism (VTE) is a major cause of morbidity and mortality among patients with cancer. Although much is known about the factors that contribute to VTE risk, pre-emptive therapy in high-risk populations is clearly indicated in only a few clinical situations. Low-molecular-weight heparin is still the recommended class of anticoagulants for cancer-associated VTE. Management of VTE in patients with renal failure, hemorrhagic brain metastases, thrombocytopenia and coagulopathy remains challenging with few safe and effective alternatives. Novel oral agents are currently being investigated and may play a role in the future in the treatment of cancer-associated VTE.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22475288      PMCID： PMC4435973          DOI： 10.1586/ehm.11.86

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


  83 in total

1.  Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism.

Authors:  Casey Lee O'Connell; Pedram A Razavi; Howard A Liebman
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

2.  Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis.

Authors:  F Dentali; W Ageno; C Becattini; L Galli; M Gianni; N Riva; D Imberti; A Squizzato; A Venco; G Agnelli
Journal:  Thromb Res       Date:  2010-05-07       Impact factor: 3.944

3.  A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.

Authors:  Giancarlo Agnelli; Giorgio Bolis; Lorenzo Capussotti; Roberto Mario Scarpa; Francesco Tonelli; Erminio Bonizzoni; Marco Moia; Fabio Parazzini; Romina Rossi; Francesco Sonaglia; Bettina Valarani; Carlo Bianchini; Gualberto Gussoni
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

4.  PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

Authors:  J R Perry; J A Julian; N J Laperriere; W Geerts; G Agnelli; L R Rogers; M G Malkin; R Sawaya; R Baker; A Falanga; S Parpia; T Finch; M N Levine
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

Review 5.  Significance of hemorrhage into brain tumors: clinicopathological study.

Authors:  D Kondziolka; M Bernstein; L Resch; C H Tator; J F Fleming; R G Vanderlinden; H Schutz
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

6.  Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.

Authors:  P López-Beret ; A Orgaz; J Fontcuberta; M Doblas; A Martinez; G Lozano; A Romero
Journal:  J Vasc Surg       Date:  2001-01       Impact factor: 4.268

7.  Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.

Authors:  Herbert I Hurwitz; Leonard B Saltz; Eric Van Cutsem; James Cassidy; Jonas Wiedemann; Florin Sirzén; Gary H Lyman; Ulrich-Peter Rohr
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

8.  Use of helical CT is associated with an increased incidence of postoperative pulmonary emboli in cancer patients with no change in the number of fatal pulmonary emboli.

Authors:  Rebecca C Auer; Allison R Schulman; Scott Tuorto; Mithat Gönen; Jaime Gonsalves; Larry Schwartz; Michelle S Ginsberg; Yuman Fong
Journal:  J Am Coll Surg       Date:  2009-05       Impact factor: 6.113

9.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

10.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316
View more
  6 in total

1.  Early warning prevention and control strategies to reduce perioperative venous thromboembolism in patients with gastrointestinal cancer.

Authors:  Yun Lu; Feng-Ying Chen; Lan Cai; Chun-Xia Huang; Xue-Fang Shen; Li-Qin Cai; Xiao-Ting Li; Yong-Yan Fu; Juan Wei
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

2.  Stroke and Cancer- A Complicated Relationship.

Authors:  Jennifer L Dearborn; Victor C Urrutia; Steven R Zeiler
Journal:  J Neurol Transl Neurosci       Date:  2014

3.  Biliverdin Reductase B Dynamics Are Coupled to Coenzyme Binding.

Authors:  Natasia Paukovich; Mengjun Xue; James R Elder; Jasmina S Redzic; Ashley Blue; Hamish Pike; Brian G Miller; Todd M Pitts; David D Pollock; Kirk Hansen; Angelo D'Alessandro; Elan Zohar Eisenmesser
Journal:  J Mol Biol       Date:  2018-06-20       Impact factor: 5.469

Review 4.  Cancer-associated thrombosis: an overview.

Authors:  Ghaleb Elyamany; Ali Mattar Alzahrani; Eman Bukhary
Journal:  Clin Med Insights Oncol       Date:  2014-12-04

5.  Silver nanoparticles promote procoagulant activity of red blood cells: a potential risk of thrombosis in susceptible population.

Authors:  Yiying Bian; Keunyoung Kim; Thien Ngo; Inho Kim; Ok-Nam Bae; Kyung-Min Lim; Jin-Ho Chung
Journal:  Part Fibre Toxicol       Date:  2019-02-14       Impact factor: 9.400

Review 6.  Cancer-Associated Thrombosis: A New Light on an Old Story.

Authors:  Sidrah Shah; Afroditi Karathanasi; Antonios Revythis; Evangelia Ioannidou; Stergios Boussios
Journal:  Diseases       Date:  2021-05-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.